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 Abstract 
Background: Identifying Mild Cognitive Impairment (MCI) and Alzheimer’s Dementia (AD) in 
the Primary Care Practice (PCP) setting can initiate intervention early, before negative 
consequences occur including decreased quality of life and caregiver burden. 
Purpose: To identify individuals at risk for AD and initiate early treatment and intervention. 
Methods: The Montreal Cognitive Assessment (MoCA) and Functional Activities Questionnaire 
(FAQ) were used as screening tools; adults age 65 and older were participants. 
Implementation Procedure: Within the Internal Medicine Clinic, the standard annual wellness 
visits include Registered Nurses that administer a Mini-Cog screening tool with the patients.  
The Mini-Cog is a brief screening tool that is currently used in practice to screen for cognitive 
impairment using memory recall and a clock drawing test. The DNP student and Registered 
Nurses in the clinic, who have been trained by the DNP student, administered the MoCA and 
FAQ to participants who scored poorly on the Mini-Cog test during their annual wellness visits.   
Results: With a two-tiered process instated, the sensitivity and specificities were improved with 
patients that failed the Mini-Cog and then went on to do screenings using the MoCA/FAQ. 
Discussion: It is recommended to use the two-tiered process to initiate further screening with the 
MoCA/FAQ if a patient fails the Mini-Cog screening. 
Implications into Practice and Conclusions: In practice, this may help to more efficiently and 
effectively screen for cognitive impairment and help patients receive referrals and/or further 
testing in a timely manner. 
  Keywords: Alzheimer’s, Alzheimer’s screening, outpatient, primary care practice, 
Alzheimer’s screening cognitive test, 65+ years. 
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Alzheimer’s Dementia Screening in Primary Care: 
Quality Improvement Project to Identify Those at Risk  
 
Introduction 
 Alzheimer’s Dementia (AD) is continuing to grow in prevalence as the population ages 
both at the national and international levels (Alzheimer's Association, 2015).  Most patients with 
dementia receive medical care in the primary care setting, but caregivers and primary care 
practitioners often fail to recognize and respond to dementia symptoms (McCarten et. al, 2012).  
Dementia diagnosis can be delayed due to the need for extensive workups and diagnostics as 
well as time constraints and limited resources.  Dementia is different than other diagnoses 
because those who are affected often do not recognize the signs and symptoms due to the disease 
process.  Recognizing symptoms is also different from the process of dementia screening.  A 
screening process is a specific type of testing that is conducted on a specified population (for 
example, adults age 65 or older) regardless of symptoms or suspicion of disease from caregivers 
or providers (Brayne, Fox, & Boustani, 2007).   A systematic screening process that is validated 
nationally by a set of Alzheimer’s-specific guidelines will help to identify those patients at risk 
for or with AD.  Early screening and intervention by primary care providers can have an 
important impact that includes reducing distress in caregivers and reducing behavioral symptoms 
in individuals with dementia (Brodaty & Arasaratnam, 2012).  Current geriatric health care 
policy should focus on the prevention and early identification of high risk/new onset cognitive 
changes, which may potentially lead to improved quality of life for dementia patients and their 
families/caregivers (Gitlin, 2012). 
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Background 
 AD is the sixth leading cause of death in the United States and the fifth leading cause of 
death in Americans of age 65 and older (Aigbogun, Stellhorn, Krasa, & Kostic, 2017; 
Alzheimer’s Disease International, 2011; Thies & Blellar, 2012; National Institutes of Health, 
2013).  There is significant financial impact that comes with this increased incidence.  Medicare 
payments for AD beneficiaries are three times greater than Medicare payments without AD 
beneficiaries.  For Medicaid, it is 19 times as great (Alzheimer’s Association, 2015; Thies & 
Blellar, 2012).  Costs are expected to continue to rise, and Social Security is not replacing this 
money for Medicare and Medicaid fast enough to fill the need.  In 2016, total direct costs for 
persons with AD and dementia was estimated at $236 billion (Aigbogun, Stellhorn, Krasa, & 
Kostic, 2017).  It is projected that, by 2050, Medicare costs will be estimated around $1 trillion 
(Brayne, Fox, & Boustani, 2007).   
 The State of Minnesota has taken direct action in an effort to improve the future for 
Alzheimer’s patients and to curb costs associated with dementia.  In 2009, the Minnesota 
Legislature charged the Minnesota Board on Aging with establishing the Alzheimer’s Disease 
Working Group (ADWG) to make policies and programs in preparation for the future.  The 
ADWG developed recommendations for legislature by 2011.  Based on this, the organization 
ACT on Alzheimer’s was formed.  It is an organization that tracks and maintains clinical and 
financial impacts of Alzheimer’s and dementia in the state of Minnesota.  The economic model 
tracks individuals as they move through various and diminishing health states and the 
accumulative costs that are accrued (Folds & Long, 2014).  Investing in early prevention 
programs may lead to significant decreased health care cost both nationally and within the state 
of Minnesota that can be tracked primarily to early screening.  These measures not only reduce 
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the costs for insurances and governmental costs, but also reduce individual facility costs both in 
primary and long-term care settings.  Early prevention in patients can lead to longer life, 
increased quality of life, and decreased caregiver burden. Prevention and recognition is initiated 
as a result of screening. 
 Because of lack of awareness of current evidence-based screening practices as well as 
treatment options for AD, primary care providers often miss the symptoms of AD due to the lack 
of understanding the current medical therapies available for dementia (Cordell et al. 2013).  
Screening individuals during annual wellness visits can help to identify these patients and 
promote early intervention.  Nurses are in an ideal position as their relationships with patients are 
based on trust and their consistent interactions with older adults and their families.  This trust 
yields the information for assessment and to conduct AD screenings.  Once patients are 
identified as at-risk, providers can present information to both patients and caregivers towards 
treatment options, further testing, and some possible ways of slowing down the progression of 
the disease.  Then they are able to offer individualized interventions, which are shown to be more 
effective at earlier onset, and help patients to make difficult decisions regarding their future care 
while they still have that capacity. 
 One type of intervention that providers may recommend is medication management.  The 
medications that are approved in the United States for AD are typically symptom management 
medications.  Many medications have increased efficacy the earlier treatment begins (Brayne, 
Fox, & Boustani, 2007).  Throughout the years, antipsychotic medications have been used in an 
attempt to alleviate behavior disturbances that oftentimes plague those with dementia.  Using 
antipsychotics, however, can increase rates of mortality, Parkinsonism, tardive dyskinesia, 
diabetes, and cerebrovascular events (Kales, Zivin, Kim, et al., 2011).  Currently, there are five 
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drugs that have been approved by the U.S. Food and Drug Administration for treatment of 
Alzheimer’s and/or to prevent or slow progression of the disease.  Drugs used to treat the 
cognitive symptoms include Aricept, Exelon, Razadyne, and Cognex.  Namenda is another 
medication that works somewhat differently in targeting the NMDA-receptors and acts as an 
antagonist.  Usually, Namenda is the only medication of these that has shown some benefits in 
the later stages of dementia while the others have shown some benefits if started in the early 
stages.  (Kumar, Singh, & Ekavali, 2015).  In addition to the many approved medications for 
symptom management, there are also trial medications being researched in studies funded by the 
National Institutes of Health (NIH).  Other trials taking place nationally include anti-amyloid-
beta interventions, which are thought to help earlier forms of Alzheimer’s (early-onset), as well 
as Alzheimer’s patients who are believed to have buildup of amyloid plaque in the brain.  
Amyloid plaque is thought to interfere with the brain cells, and these medications are showing 
some encouraging results (NIH, 2012). 
 Offering screening to individuals age 65 and older who may have Mild Cognitive 
Impairment (MCI) and do not yet have AD will also help to identify at-risk individuals since 
MCI can be a precursor or leading risk factor for development of AD (Albert et al., 2011).  
While it is not definitive that MCI will become AD, it is something that providers should 
investigate for a cause.  If no medical or psychiatric condition is determined to be contributing 
and if it is determined to be MCI, further monitoring is warranted.   
 There are several guidelines for diagnosing MCI, including those from the National 
Institute on Aging-Alzheimer’s Association (NIA-AA) (Albert et al., 2011), Diagnostic and 
Statistical Manual of Mental Disorders (5th edition; DSM-V) (American Psychological 
Association), and the International Work Group (IWG) (Dubois et al., 2010).  Regardless of the 
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guideline that is used, MCI is identified as a risk factor for Alzheimer’s disease.  While some 
patients do not progress and some even improve cognition, it is important to identify these 
individuals early and follow their progress as well as offer any needed interventions.  These are 
patients who benefit from earlier recognition through screening, and, although the screenings can 
be offered, there is still a lack of this being done to the full potential in primary care practices.  
Therefore, by implementing consistent screening, Alzheimer’s patients identified earlier can 
ensure improved quality of life, lower health care costs, and decreased caregiver burdens. 
Problem Statement 
 The risk of increased morbidity and earlier mortality for persons aged 65 years and older 
secondary to diagnosis of AD is evidenced by increased incidence and prevalence of 
diagnosis of AD in the baby boomer population and others living to older ages.  AD is associated 
with pronounced cognitive decline, physiologic sequelae, and decreased quality of life.  Lack of 
early screening and delayed effective intervention for AD by providers can contribute to a more 
prolonged and significant course.  A quality improvement project was implemented for 
individuals age 65 years and older in the primary care setting with the goal of increasing the use 
and efficacy of AD Screening. The screening tools used were a combination of the MoCA 
(Appendix A) and the FAQ (Appendix B) screening tools. 
Organizational “Gap” Analysis of Project Site  
 The community of interest (COI) included people age 65 and over and within an adult 
primary care Internal Medicine Clinic.  This clinic is located in Duluth, MN, where there are 
more than 19,000 patients and seven physicians.  There are annual wellness visits conducted 
almost daily and usually several within the day.  These are visits paid by Medicare where the 
patient sees a nurse and discusses his or her daily routines and lifestyle.  Encouragement, 
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education, and modifications are discussed between the nurse and the patient involving physical 
activity, healthy eating, stress reduction, safety in the home, and resources for services.  There is 
also a Mini-Cog exam that is performed (Appendix C) and scored out of five points.  The Mini-
Cog is a screening tool that is used to assess any basic cognitive limitations or decline.  
However, there is no further testing that is performed if the patient has a low score or scores 
poorly on the Mini-Cog screening, but the results are given to the physician to decide how to 
further investigate the findings.  On site in this facility are pharmacists, nursing staff, and 
scheduling staff.  The facility is adjacent to the hospital in the event a patient may need transport 
to a higher level of care.  There are many different specialty offices, radiology, and an infusion 
center next to this office if these services are needed for patients. 
 This QI project aimed to help to identify at-risk individuals who are age 65 and older who 
may not otherwise receive a risk assessment for Alzheimer’s Dementia. The project goals 
included bringing about meaningful change by having clinics begin to implement routine 
dementia screening for older adults. 
 The screening tools that were used were a combination of the MoCA and FAQ screening 
tools.  Using these two screening tools together can be more accurate, effective, and precise in 
identifying at-risk dementia patients (Cruz-Orduña et al., 2012).  The Internal Medicine site in 
Duluth, MN currently uses these screening tools only when the provider specifically decides to 
perform them.  There are annual wellness exams that are given where the patient sees the nurse, 
and they have a Mini-Cog screening performed. Thus, there exists an opportunity to go one step 
further. If the patient performs poorly on the Mini-Cog, the next step would be to use the MoCA 
and FAQ screening tools (Nasreddine, Phillips, & Chertkow, 2012; Pfeffer, Kurosaki, Harrah, 
Chance, & Filos, 1982).  This would also save time and effort for the providers.  Although many 
ALZHEIMER’S DEMENTIA SCREENING 12 
of the patients are in the age groups that are seen at the clinic site, there is not much emphasis 
placed on screening or dementia care.  
Review of the Literature 
Method 
 A comprehensive search of the literature for AD evidence included the following 
databases: PubMed of the National Library of Medicine, Cochrane, and Cumulative Index to 
Nursing and Allied Health Literature (CINAHL).  The following Medical Subject Headings 
(MeSH) terms were used for the PubMed search: Alzheimers and Alzheimers screening.  To 
delimit the search, the terms outpatient and primary care practice were used within the search 
databases.  Within PubMed, Alzheimers screening cognitive test and further delimiting to in 
primary care narrowed findings to six results. The CINAHL search was delimited using criteria 
of 65+ years and outpatient.  Narrowing CINAHL produced seven results.  Cochrane returned 
two results with the search Alzheimers.  All references used have either a grade A or B in the 
quality of evidence, and levels were dependent on the type of study according to the Johns 
Hopkins Nursing Evidence Based Practice (JHNEBP) Rating Scale (Newhouse, Dearholt, Poe,  
Pugh, & White, 2005). 
 Inclusion criteria included full-text articles published in the English language.  The age of 
the subjects studied was identified as 65 and older.  Due to the rapidly changing research in AD, 
the majority of studies were identified from the last five years (2012-2017). 
Screening Tools 
 The use of many different screening tools for cognitive decline and AD has been 
evaluated throughout the years (Alzheimer’s Association, 2003; Cordell et al. 2013; Costa et al. 
1996; Cullen, O’Neill, Evans, Coen, & Lawler, 2007). The Mini-Mental Status Exam (MMSE) is 
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a common and well-known tool that is used internationally (Folstein, Folstein, & McHugh, 
1975).  MoCA is well known and gaining more reputability internationally as it is used in more 
than 100 countries around the world (Nasreddine, Phillips, & Chertkow, 2012).  Saint Louis 
University Mental Status (SLUMS) is another well-known screening tool that is useful in 
detecting dementia and MCI (Tariq, Tumosa, Chibnall, Perry, & Morley, 2006).  The Mini-Cog 
is a shorter screening tool that, while not as specific or sensitive, has a shorter timeframe of three 
to five minutes (Borson, 2015).  Included in the Mini-Cog is the Clock-Drawing Test (CDT), 
which can also be a tool used on its own for cognitive impairment screening (Agrell & Dehlin, 
1998).  The FAQ is another screening tool that is similar to the Activities of Daily Living (ADL) 
in that they both assess the abilities of the individual to perform tasks in their own living 
environment in how dependent or independent they function, whereas some of the cognitive 
screening tools neglect this area (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982).  
 Many providers in primary care clinics are using the Mini-Cog test since it is a fast and 
relatively easy screen to administer.  Another relatively quick and easy screening tool that has 
been developed and validated is the Rapid Cognitive Screen (RCS).  It is less than three minutes 
in length and involves recall, clock drawing, and insight.  Malmstrom et al. (2015) evaluated this 
screening tool in sensitivity and specificity in detecting MCI and dementia on the Diagnostic and 
Statistical Manual IV (DSM-IV) and SLUMS and validity for nursing home placement and 
mortality.  AUC scores showed that the RCS is a better predictor overall of dementia and MCI 
on the DSM-IV with the largest difference shown in the MCI population.  In comparison to the 
CDT, the CDT has not been involved in studies that can validate if that is a reliable measure of 
identifying MCI.  While SLUMS has been shown to have good sensitivity and specificity for 
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dementia and MCI, it takes about six to eight minutes to administer, and RCS is a rapid version 
of this test. 
 One barrier in dementia screening that may be anticipated is a resistance from the patient 
population.  While screening can be helpful for caregivers, patients may feel scared that they will 
be labeled or fear repercussions from insurance companies.  However, Holsinger, Boustani, 
Abbot, and Williams (2011) found that more than 81% of primary care patients indicated that 
they would actually want to be screened to determine if they are developing dementia.  They 
then provided the patients with education regarding the risks and benefits of screening, and the 
number of patients who wanted to be screened increased to 86%.  Rasmussen and Iliffe (2014) 
argue between the pros and cons of general practitioners conducting screening for dementia, but 
both agree that dementia and cognitive impairments are a growing international issue.  In 
screening individuals in primary care, where patients come to have a general wellness check and 
trust that their concerns are being addressed, the practitioners are in a privileged role that can 
help these individuals early on. 
Dementia Risk Score 
 A recent study by Walters et al. (2016) looked at a Dementia Risk Score between patients 
in the United Kingdom (UK) from PCPs. Using the algorithm developed in this study, the 
screening tool identified higher risk populations for dementia in PCPs.  The data showed that the 
Dementia Risk Score was able to make a strong relationship with the risk of developing 
dementia in the next five years using a scoring system.  Among the drawbacks of this study is 
that it is a newer developed screening tool, so the validity needs to be tested more rigorously 
before it can become a tool that is implemented into practice.  Also, the study was performed in 
the UK, where the population studied may not be generalizable to populations in the United 
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States. The Dementia Risk Assessment algorithm that was developed from this study seems to 
combine many of the mental status questions and activities of daily living questions that are used 
in other cognitive screening tools.  It may be the direction of the future if validation studies 
continue to implement this risk assessment tool.  
Instruments for Dementia Screening 
 The MMSE was developed in 1975 for differentiating between functional and organic 
disorders in psychiatric patients (Folstein et al., 1975).  Today, it is most widely used as a 
cognitive screening instrument in the Unites States and many other countries (Cullen et al., 2007; 
Tombaugh & MacIntyre, 1992).  Cordell et al. (2013) reviewed 15 different cognitive assessment 
tools that have been evaluated in multiple review articles for the purpose of implementation in 
the primary care setting for annual wellness visits.  They found that, due to time constraints, 
limitations with different screenings, and proprietary issues, the most recommended screenings 
would be the General Practitioner Assessment of Cognition (GCOG), Mini-Cog, and Memory 
Impairment Screen (MIS).  However, the recommendations according to the Alzheimer’s 
Association algorithm are that once a cognitive impairment is suspected, a full assessment and 
evaluation for dementia should occur.  While not one tool is recognized as the best assessment 
tool, the MMSE, SLUMS, or MoCA can be used to further evaluate dementia and its severity.  
Stewart, O’Riley, Edelstein, and Gould (2012) compared the MMSE, SLUMS, and MoCA.  
They found that, while the MMSE continued to have reliability and accuracy in screening for 
dementia, the SLUMS and MoCA addressed some cognitive skills that are not addressed in the 
MMSE.  Limitations associated with the MMSE include that it is licensed by the Psychological 
Assessment Resources (PAR) (Holsinger, Deveau, Boustani, & Williams, 2007; Powsner & 
Powsner, 2005).  PAR does not allow the MMSE to be copied from an unlicensed source, but 
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rather it must either be purchased or administered from memory.  This limitation can be a 
difficult hurdle with implementing screening processes in primary care, so the SLUMS and 
MoCA are also well established and used public screening tools that are available.  Because the 
MoCA is highly sensitive and reliable, as well as free for clinics to perform, it is a more enticing 
package for practitioners and facilities to choose as a screening tool. 
 Brown, Joliffe, and Fielding (2014) evaluated the MMSE and the Functional 
Performance of Inpatients (FIM) to see if there was an association between the two.  They found 
that the MMSE scores for inpatients were significantly associated with the total FIM scores.  The 
FIM scores are used for inpatients to determine a patient’s functional capabilities upon discharge.  
This scale is similar to the FAQ in that they both examine functional capabilities.  The MMSE 
scores are shown to be associated both in the FAQ and the FIM scores, and FAQs are more 
appropriate in the outpatient setting.   
 Del Campo et al. (2016) conducted two investigations in France comparing the MMSE 
and the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) screening tools 
for the PCP setting.  ADAS-Cog measures the severity of AD symptoms but is most widely used 
in clinical trials and has less responsiveness with MCI. (Skinner et al., 2012).  The results of the 
ADAS-Cog screening tool showed that there was a great likelihood that it was able to predict 
whether a patient with mild to moderate AD was likely to develop cognitive decline over the 
next two years.  The ADAS-Cog and the MMSE are both tools to measure cognitive impairment; 
however, the MMSE is more widely accepted for the use in PCPs.  (NIH, 2012). While the 
MMSE remains a widely used tool, it also is generally used more for comparisons with previous 
MMSE scores and comparisons with other patients while there are newer screening tools for 
cognitive impairment that are more sensitive and specific.  
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 The MoCA screening tool is a newer developed tool, validated in 2005 to assess the 
cognitive functioning or impairment with MCI and AD in a relatively short time frame – about 
10 minutes (Nasreddine et al., 2005).  Studies have evaluated different screening tools against 
one another in attempts to find what is most preferred.  While no one screening tool is 
recognized as the gold standard for MCI and AD, the MMSE, MoCA, and SLUMS are among 
many providers’ preferences.  Cummings-Vaughn et. al (2014) examined a comparison between 
a short test of the Mental Status Exam, SLUMS and MoCA and found they all had similar 
validity with the detection of MCI or dementia according to the Clinical Data Rating Scale 
(CDR).  In another comparison study, the SLUMS, MMSE, and MoCA were compared in the 
detection of cognitive impairment (Cao et al., 2014).  The findings in this comparison showed 
that the SLUMS scores are fairly consistent with the MoCA. 
Functional Activities Questionnaire 
 The FAQ is an attractive screening instrument because it is easy to administer and aids in 
the detection of cognitive impairment by being able to differentiate between cognitively normal 
individuals and those with dementia (Steenland et al., 2008).  The MMSE, MoCA, SLUMS, 
FAQ, the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), and the 
ADAS-Cog are among the most-used AD screening tools (Alzheimer’s Association, 2003; 
Cordell et al., 2013; Costa et al., 1996; Cullen et al., 2007).  More recent studies are investigating 
the effectiveness of the different tools in the PCP setting since it is identified that early detection 
of AD can yield improved outcomes.   
 Another study by Cruz-Orduña et al. (2012) examined the combination of three validated 
and reputable cognitive evaluation screening tools: the MMSE, IQCODE, and FAQ.  Sensitivity, 
specificity, and area under the curve (AUC) were measured. AUC, using the MMSE and the 
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FAQ, was 0.95, which was indicative of very strong certainty of reliability.  Old methods and the 
use of one type of screening tool can miss possible cognitive impairments in AD patients who 
may have otherwise been identified.  This study had findings similar to the sensitivities and 
specificities of many other research studies that evaluated these tools (Shulman et al., 2006).  
However, it is clear that with a combination of the tools, the outcome is improved.  The study 
found the IQCODE to not be as helpful and determined that the combination of the MMSE and 
the FAQ was the best to detect AD.  While this study was conducted between associations of 
combining the MMSE and FAQ as having improved sensitivities and specificities, it would seem 
that similar results could be achieved by combining different types of screenings to assess both 
cognitive functioning and mechanical functioning. 
Biomarkers and Frequency Doubling Technology 
 Currently, much headway is being made in the research of biomarkers. Some studies are 
proposing that, with biomarkers, AD can be identified before there is clinical indication or 
symptoms (NIH, 2012; Monge-Argilés et. al, 2016; Mortamais et al., 2016).  In 2012, the NIH 
put forth much effort and funding to support Alzheimer’s research and medications for patients 
who are positive with the APOE4 allele, best known for a risk with late-onset type of 
Alzheimer’s.  This study will test through imaging and biomarker techniques to identify faster 
ways to evaluate prevention therapies in the future (NIH, 2012).  Results in a Spanish population 
study by Monge-Arguilés et al. (2016) found that APOE4 status is associated with lower CSF 
A𝛽42 as well as higher CSF T-tau and p-tau protein levels and tau/A𝛽 ratios, in patients in the 
early stages of AD and in control subjects. However, the presence of APOE4 does not seem to be 
a deterministic factor for the development of AD, with results being inconclusive (Kester et al., 
2009; Popp et al., 2010; Vemuri et al., 2010).  Biomarkers that are being investigated include 
ALZHEIMER’S DEMENTIA SCREENING 19 
variants in the CSF, abnormal tracer retention on amyloid positron emission tomography (PET) 
imaging, decreased flurodeoxyglucose (FDG) uptake on PET imaging, and atrophy seen on 
magnetic resonance imaging (MRI) (Martínez-Torteya, Treviño, & Tamez-Peña, 2015).   
 Mortamais et al. (2016) explored the feasibility of detecting signs of dementia in a 
preclinical phase, or the start of MCI. Biomarkers with correlating memory decline, and Igh 
levels of amyloid deposition were identified as having positive associations.  There are also 
several bias and other factors that can account for these changes that may not be indicative of 
AD.  The conclusions of this study were not able to determine if the criteria for preclinical AD 
staging would further improve outcomes or help to understand AD at this time.   
 Valenti (2013) investigated early functional biomarkers of AD using a technology called 
Frequency Doubling Technology (FDT).  FDT is a type of visual testing that assesses the nerves 
in the eye and brain.  Valenti was able to conclude that there is a strong likelihood that FDT can 
be useful in ruling out individuals that may need additional workup, including AD testing, if they 
fail FDT testing.  However, biomarkers can also be indicative of other neurodegenerative 
diseases.  The use of biomarkers in the outpatient PCP setting is not realistic because this type of 
testing can be costly.  Insurance providers are not likely to promote these types of testing, and 
there is fear from patients that this type of testing can alter their abilities to hold driver’s licenses 
and also may interfere with insurance premiums (Thies & Blellar, 2012).  In comparison to 
cognitive screening tests, the applicability for screening tests within the PCP office is a more 
feasible and cost-effective approach. 
Telephonic Assessment Questionnaires 
 Royall, Velez, and Salazar (2012) conducted a telephone study with participants to screen 
for MCI and AD.  They used the Alzheimer’s Questionnaire (AQ) with the Telephone Executive 
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Assessment (TEXAS), Telephone Interview for Cognitive Status-modified (TICS-m), and 
Buschke Memory Impairment Scale (telephone version) (MISt) as predictors of MCI and AD.  
These screenings were not as sensitive to distinguish MCI and AD via telephone. Many patients 
and caregivers of AD are not able to come into clinics for testing, or it can be a very cumbersome 
process.  This study addressed that gap in practice and aimed to capture more data.   In doing so, 
it sought to validate the need in the community for increased MCI and AD resources and 
assistance.  Using a telephone method is more effective and efficient in screening due to logistics 
where both the patients and the caretakers do not have to leave home.  Sometimes caretaker 
burden may prevent caretakers from bringing in a patient, even when they know they need more 
resources.  With these telephone assessments, the caretaker is able to provide the information 
over the phone and may have more insight than the patient into the degree the dementia is 
affecting the patient.   
 This study was furthered two years later with the same authors and found that the use of 
the Alzheimer’s Questionnaire over the phone was able to distinguish to a modest degree 
between patients with MCI and those without (Salazar, Velez, & Royall, 2014).  The addition of 
the TEXAS allowed more information to be gathered in relation to the severity of the dementia. 
 The modified telephone interview for cognitive status (TICS-m) is another widely used 
screening instrument that is used for Alzheimer’s dementia.  This telephone interview was 
modeled after the MMSE due to the difficulties that face-to-face administration of screening 
tools pose, especially for those with cognitive or physical limitations.  However, while this is a 
screening instrument that works well for those limitations, it is still found to have generalizable 
data regarding cognition as well as memory functioning (Van der Berg, Ruis, Biessels, Kappelle, 
& Van Zandvoort, 2012). 
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 There are many different screening tools in place for the PCP setting to help to identify 
MCI and AD as well as newer screening tools to assess for the risk in developing these cognitive 
impairments.  The studies show promising results in each assessment.  When comparing and 
contrasting the applicability of the screening tests, PCP offices will need screening tools that are 
feasible for use.  The use of biomarkers, while an exciting part of ongoing research, is not a cost-
effective solution for use in PCPs.  FDT is another exciting research initiative, but this also is not 
a cost-effective screening tool for PCPs.  When reviewing the many different available screening 
tools in use for MCI and AD, practitioners will want a widely used and validated tool such as the 
MMSE, SLUMS, Mini-Cog, MoCA or GCOG.  While the Dementia Risk Score has many 
promising uses for the future, it has not been validated enough times to be recommended within 
the national guidelines as of yet.  The telephone assessments are another interesting and 
important way to capture more information.  However, they would be most useful in assessing 
changes in known MCI and AD patients rather than identifying patients.  The gold standard of 
screening tools remains to be with more validated and used screening tools.  While each 
screening tool has some limitations, the MoCA is a validated and widely recognized tool that has 
shown great results for specificity and sensitivity as well as being free for public use.  Using a 
combination of the MoCA and the FAQ, as both validated tools, results show increased sensitive, 
specific, and yield greater AUC scores.  This also helps in overcoming the limitations that are 
faced in only using one type of screening tool since each has different strengths and emphasis to 
get a better overall sense of a person’s risk factors and impairments.  This would help to identify 
and capture more cases of MCI and AD within the PCP and, in turn, help those individuals to 
receive earlier care and interventions when needed. 
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Evidence Based Practice: Verification of Chosen Option for Dementia Screening 
 Based on the review of the literature, a combination of two validated screening tools were 
used to screen individuals at risk for dementia.  The MoCA and FAQ tools in combination are 
sensitive and reliable for detecting early MCI and AD. 
Theoretical Framework/Evidence Based Practice Model 
 Kurt Lewin’s three-step model for change is a strategy to bring about a desired change in 
a workplace and help others to see why and how the change is needed (Lewin, 1951; Appendix 
D).  The model is divided into three steps: unfreezing, moving, and refreezing.  Unfreezing is 
first by introducing the desired change to nurses and providers, which would be the use of the 
screening tools. (Lewin, 1951).  In introducing this intervention, it is important to create a sense 
of safety that this change will bring about better outcomes.  Jost (2015) examined the 
psychological resistance to change and the application of Lewin’s theory as still being a relevant 
and working model in helping alleviate that resistance and transition into the desired change.  
Marshak (2012) writes about using the Lewin theory of change in his practice with much success 
as well as integrating Korean theories and Eastern cultural teachings.  When introducing this 
Quality Improvement project to nurses and providers, the prevalence of Alzheimer’s disease and 
devastation it causes in the health care sector and with families should be stressed.  By using a 
screening tool to identify at-risk individuals at an earlier time, this can be prevented, and 
outcomes can be improved.  This safety is created when there is recognition that change will 
bring better outcomes and is necessary for the future care of the growing population. It may also 
create a sense of guilt for not having used these interventions before, but Alzheimer’s Dementia 
is an important issue that needs more recognition and will ultimately bring about a better change 
for the future in how caregivers recognize and treat this disease.  The moving stage provides 
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more information on how this change will come about, such as the logistics of how the screening 
will happen and what types of tools will be used.  This will be achieved by educating the nurses 
and staff regarding AD and the screening process that will be implemented.  Then, there is the 
shift of actually implementing the change into practice (Manchester et al., 2014). This step will 
occur when the nurses and staff begin to implement the screening process within their daily 
workday with patients.  Once the process actually begins and the nurses start to have a more 
tangible relation with screening individuals, they will start to understand how it can improve 
their practice, improve the workload for providers, and improve patients’ outcomes overall.  
Refreezing is the last phase, and this involves implementing the new system and any 
modifications needed.  While the nurses are implementing the screening process, they may see 
changes that are needed or have ideas in modifying the project.  There will be focus groups to 
allow for the exchange of ideas and any changes that need to take place to make the project work 
well for the site.  This will also help to make the project more generalizable and repeatable for 
future sites to implement. 
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Goals, Objectives and Expected Outcomes 
Goal 1: Nurses will be educated to administer MoCA and FAQ screening tools. 
Objective Expected Outcome Result 
Nursing meeting with DNP 
student and nurses. 
First meeting will be held 
by 10/30/17. 
Met: Meeting held and 
successful. 
Sample MoCA and FAQ 
screening tools reviewed 
with nursing. 
MoCA and FAQ screening 
tools have several samples 
and opportunities for 
nursing to practice. 
Met: Screening tools 
reviewed with nursing and 
opportunities for questions 
and practice given. 
MoCA and FAQ tools have 
locked area in nursing 
station for nursing to store 
when completed. 
Secured area in nursing 
station designated by 
11/6/17. 
Met: Secured area with key 
lock in cabinet within the 
Elder Care department.  
Nurses kept the key in the 
Complex Care RN office. 
 
Goal 2: Nursing and the DNP student will meet in focus groups to address any issues or 
concerns. 
Objective Expected Outcome Result 
Nursing meeting with DNP 
student and nurses. 
First meeting will be held 
by 10/15/17. 
Met: Meeting successful. 
Monthly meetings between 
nursing staff, DNP student, 
and nurse practitioners. 
30% of staffing will attend 
meetings to address any 
concerns or issues with the 
screening process. 
Met: Focus meetings met 
monthly with 90% of 
essential staff.  
DNP student and Providers 
oversee the screening 
process. 
Nursing staff will alert the 
health care provider (i.e., 
Nurse Practitioner, 
Physician Assistant or 
Physician) when there are 
positive screenings. 
Met: Providers notified of 
positive screening.  
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Goal 3: Health care providers will benefit from the use of these screening tools in early 
identification of Alzheimer’s Dementia patients.  
Objective Expected Outcome Result 
Health care providers will 
enhance the identification 
of Alzheimer’s Dementia 
patients through the 
screening tools. 
Nursing will administer the 
screening tools 90% of the 
time to persons in 
population of interest. 
Met: 100% of population of 
interest was administered 
screening tools. 
Health care providers will 
enhance the identification 
of Alzheimer’s Dementia 
patients through the 
screening tools. 
25% of health care 
providers will report that 
using the screening tools is 
useful in the clinical setting. 
Met: 86% of providers 
agreed the screening tools 
are useful (6/7 providers). 
 
Goal Related to Effectiveness 
Goal 4: Health care providers will find the combination of the MoCA and FAQ to be more 
effective of a screening tool than the Mini-Cog 
Objective Expected Outcome Result 
The combination of the 
MoCA and FAQ are more 
effective than the Mini-Cog. 
Increased Specificity levels 
measured. 
Met: Increased Specificity 
levels were seen with the 
MoCA and FAQ 
screenings.  
 Increased Sensitivity levels. 
Met: Increased Sensitivity 
levels were seen with the 
MoCA and FAQ 
screenings. 
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Goal Related to Population 
Goal 5: Persons 65 and older will have positive experiences with the screening tools and 
process. 
Objective Expected Outcome Result 
Persons of age 65 and older 
will have opportunity to 
consent to or refuse 
screening. 
95% of individuals of 
interest will consent to 
screening.   
Met: 100% of individuals of 
interest consented to 
screening. 
Persons of age 65 and older 
will have an opportunity to 
discuss results of screening 
with a health care provider. 
95% of participants will 
receive counseling and 
education regarding the 
results. 
Met: 100% of participants 
were offered counseling and 
education regarding results. 
 
 
Project Design 
 This DNP project has a Quality Improvement (QI) project framework and an educational 
evaluation design that was set up to address the gap in practice through screening individuals and 
implementing education-based findings.  The nurses were educated by the DNP student in 
administering the MoCA and FAQ screening tools with patients who were within the criteria.  
The criterion, as stated earlier, is persons of age 65 and older who consent or another designated 
person that has Power of Attorney (POA) to consent for screening.   
 To obtain the desired outcome, there was education for the nurses and ongoing focus 
groups with nurses and practitioners to review feedback during the project course.  Using the 
feedback in focus groups, the project was modified to the site as needed.   
Project Site and Population   
The project took place at an Internal Medicine primary care clinic in Duluth, MN.   In the 
Internal Medicine Clinic, the nurses who administer annual wellness exams included this in their 
review with the patients.  Before, there was a Mini-Cog screening tool that the nurses 
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administered.  In the interest of time management, the MoCA and FAQ were not given unless the 
person performed poorly on the Mini-Cog, indicating possible cognitive impairment. 
  The Internal Medicine Clinic in Duluth, MN is a large primary care clinic with around 
19, 000 patients from both Minnesota and Wisconsin.  This clinic provides for a large spectrum 
of the community.  Many people are willing to travel to Duluth for services because it is owned 
by Essentia Health and is a Level II trauma center.  The closest Level I trauma center is in 
Minneapolis, MN, which can be much further for people.   
 Participants were selected at each site with the criteria of being age 65 or above and have 
given consent (or consent of the POA).  Those with known AD who are currently receiving 
treatment were excluded, as well as psychiatric or cognitive issues that are diagnosed that could 
impair or skew results.  Examples of psychiatric exclusions included severe depression, 
schizophrenia, Post-Traumatic Stress Disorder, and any anxiety disorder that the patient is not 
able or willing to participate.  Examples of cognitive conditions that were excluded were 
Traumatic Brain Injuries, Down Syndrome, Autism, and developmental disorders that prevented 
the patient from participating, and any type of neurocognitive disorder that prevented the patient 
from participating.  The sample size was 14 participants with the inclusion and exclusion 
variables as well as screening only the adults that accepted doing the annual wellness visit and 
further screening. 
 The Internal Medicine Clinic is organized according to physicians.  Each physician and 
Advanced Practitioner (AP) is organized into care teams.  Each care team has two to three nurses 
who help to direct patient calls and results to patients in an organized and timely fashion.  There 
are several Warfarin nurses that strictly work by protocols with patients who are on Warfarin and 
need their dosages adjusted according to their International Normalized Ratio (INR).  There are 
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also two separate complex care Registered Nurses (RN) who conduct annual wellness visits, 
walk-in visits, and any additional ancillary needs (suture removals, wound care, Mantoux reads, 
etc.).  The clinic is open from 8:00 a.m. until 5:30 p.m. and different practitioners have schedules 
that are worked out among one another.  When one physician is away, another from the same 
care team will cover any patient needs.  Nurses are scheduled from 8:00 a.m. to 4:30 p.m. and 
9:00  a.m. to 5:30 p.m. and and always have coverage among care team members.  In order to 
implement the project, the DNP student conducted teaching with the complex care RNs who give 
the annual wellness visits and care team/triage nurses in the instance that complex care RNs are 
unable to perform the tasks.   
Setting facilitators and barriers.  
 Conducting the MoCA and FAQ screening tools required education with the providers on 
the patient population in the area and the amount of aging population that will be falling into the 
age group for being at increased risk for dementia.  With early diagnosis and intervention, it can 
allow people to make decisions much earlier while they still have that cognitive ability to make 
those decisions.  (Alzheimer’s Disease International, 2011).  However, one barrier has been that 
practitioners and other staff members are resistant to change.  Many providers prefer to focus on 
current health issues rather than preventative care. 
 With the MoCA and FAQ screening tools, the registered nurses were the ones that 
performed the screenings with the patients.  In educating the registered nurses to administer the 
screenings, the hope was to help with time management for the providers and data collection. 
Another benefit of the RN in the annual wellness exams is that Medicare pays for those visits, so 
they were more likely to interest patients since they have no cost associated with the visit if they 
are only seeing the nurse.   
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 One early barrier that was encountered was attempting to set up an affiliation between the 
facility and the university.  The university has an Internal Review Board (IRB) that reviews the 
project proposal in relation to ethics with human research.  Once this was approved, the facility 
also had a separate IRB process to approve the project.  In addition, a separate status of being a 
student was needed to establish for the DNP student in order to gain access to the Electronic 
Health Records (EHR).  This required separate documentation of another background check, 
immunizations, health records, malpractice insurance, and information regarding student 
identification and research qualifications. This process took much longer than anticipated and 
delayed the start of the project by four months.  Due to the delay, the project was not able to 
gather as much data, but some data was able to be collected retrospectively to enhance the quality 
of data and data numbers.  
 At first some nurses did give some resistance, as this was a deviation from their normal 
schedule.  After a few patients and due to the infrequency of when this occurred, they did start to 
become more comfortable.  However, the time that it took to administer both the MoCA and the 
FAQ screening tools, especially when the patient was scheduled to see their primary care 
physician after the nurse wellness visit, was an ongoing barrier that was seen.  This, in turn, 
created some compliance issues among nurses and patients with using the screening tools on the 
population of interest.  
 With the positive screenings and this QI project, they were able to make a referral to 
either neurology or the outpatient memory clinic and/or initiate medication management in a 
more timely fashion.  However, there were some barriers encountered with this process as well.  
Some patients preferred talking to their primary care or waiting to have any referrals placed.  
Also, there were times when primary care providers preferred to do further assessments on their 
ALZHEIMER’S DEMENTIA SCREENING 30 
patients and conduct more history and decided that a MoCA assessment or further referral was 
not warranted.  Each screening was individual to the patient and there were many other factors to 
take in consideration before narrowing down to cognitive impairment.  
 There was anticipation that the practitioners may not want to focus on preventative care.  
However, with Medicare covering the annual wellness exam, this did interest more patients to 
come in, and many providers found this useful in getting overall patient wellness information and 
further screening needs.  Also, from a business standpoint, the annual wellness exams help to 
bring in great revenue for the clinic with reimbursement from Medicare.    
 Another aspect to be addressed is that nurses and/or providers did need to obtain a 
thorough health history, including any known dementia in the patient’s relatives.  The health 
history was conducted prior to annual wellness visits as part of the patient’s complete physical, 
so this was not a change to practice but rather an additional consideration with patients that were 
appropriate for screening.  A component of the annual wellness exam is a review of family 
medical history.  Many times, patients forget to mention dementia as a medical issue, but the 
nurses were prompted to ask if anyone in their family had dementia and many times this concern 
was brought up if the patient had concerns over their own memory, before assessment began. 
Implementation Procedures 
1. Nursing meeting to introduce project.  Includes nurses, nurse practitioners, DNP student, and 
physicians who wished to attend.  Explained the gap in practice with Alzheimer’s and the 
solution in using screening tools and presented with a PowerPoint presentation. 
a) Introduce screening tools to be used. 
b) Population of interest that will be screened. 
c) Obtain patient consent to be screened. 
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d) Role-play with screening tools and examples. 
e) Show staff where completed documentation in the nursing station is kept. 
2. Focus groups met prior to project, monthly, and after completion of project with nursing staff 
and providers.  
a) Emails sent to alert nurses of the focus group prior to date. 
b) Dialogue between DNP student and staff to facilitate improvement and continuation 
of the project. 
3. Data Collection  
a) DNP student provided packets within the Annual Wellness Visit packets for the nurses 
to use if the patient failed the Mini-Cog.  These packets included Drake QI Project- Data 
Intake (Appendix E), as well as MoCA and FAQ screening tools. 
b) Completed packets were placed by nursing staff into the locked nursing station 
cabinet, located within the Elder Care department. 
 c) DNP student collected packets that were kept in the locked area within the nursing 
 station.    
4. Data Analysis  
 a) Staff members issued optional surveys with the Drake Likert Scale (Appendix F) to 
determine the effectiveness and value of the screening tools used. Included an area to write in 
comments or ideas for further improvement. 
 b) Data from the screening tools compiled to determine the quantity of positive 
screenings and whether or not interventions took place.   
 c) Sensitivities and specificities calculated from the data 
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 d) Overall number of failed Mini-Cogs calculated to give percentage of population that 
would require the further screening tools, MoCA/FAQ. 
 e) Time and Cost analysis calculated for the Mini-Cog and MoCA/FAQ and compared. 
Measurement Instruments 
 In order to measure the outcomes of this DNP project, the following instruments will be 
used: Mini-Cog (Appendix C), MoCA (Appendix A), FAQ (Appendix B), and Drake Likert 
Scale (F).  
 Mini-Cog 
 The Mini-Cog is often implemented in the primary care office setting as it is a relatively 
easy screening to administer and it takes about three to five minutes to complete.  While it can 
identify some mild cognitive impairment, there is not enough data to support it in detecting MCI.  
Sensitivities, based on the studies, range from 60% to 99% (Cullen et al., 2007; Carnero-Pardo, 
Cruz-Orduña, Espejo-Martínez, Martos-Aparicio, et. al, 2013).   
 Montreal Cognitive Assessment  
 The MoCA study has been validated for international use.  Nasreddine et al. (2005) 
performed studies to evaluate the sensitivity and specificity of the screening tool.  It was found 
that the MoCA detected 90% of patients with MCI whereas the MMSE was compared and had a 
sensitivity of 18%.  With mild AD, the MoCA detected 100% and the MMSE had a sensitivity of 
78%.  Specificity was excellent for both the MMSE and MoCA, being 100% and 87%, 
respectively.  The questionnaire is easy to follow and administer.  It is limited in its ability to 
assess functional and mechanical independence or dependence. 
 Functional Activities Questionnaire. The FAQ is a functional assessment questionnaire 
that assesses what an individual is able to do at home and how much help they do or do not need 
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in order to do those functional activities throughout the day.  It is a 30-item questionnaire that is 
completed by an informant.  It can acquire valuable information as it is obtained from a reliable 
source that knows the participant well.  The questionnaire is easy to follow and self-explanatory.  
This screening tool is considered to be reliable and measures functional rather than cognitive 
abilities, which is something that can be limited with other screening tools.  It is limited in that it 
mainly focuses on functional abilities but is able to discern with a good validity the degree of a 
person’s independence or dependence.  (Steenland et al., 2008).  The FAQ was previously 
identified by the Agency for Health Care Policy and Research as having sensitivities and 
specificities in the 85-90% range in relation to identifying individuals with dementia (Costa et 
al., 1996). 
 Drake Likert Scale. This is a five-point Likert scale created by the DNP student to 
evaluate feedback from the nursing staff.  Each question has a range of answers to determine the 
effectiveness and value for this project.  The answers are as follows in order: Very Poor, Poor, 
Fair, Good, and Very Good. Very Poor receives zero points, and they each increase sequentially 
by one point with Very Good receiving four points.  The last question allows opportunity for 
suggestions to improve the project for future endeavors. The person taking the survey remains 
anonymous and rates each question according to how they feel the screening tools measured in 
their own opinions. 
Data Collection Procedures  
 Pre-Intervention. Recruitment took place by hosting a nursing meeting with the project 
mentor for nursing staff, nurse practitioners, nursing administration, and any physicians who 
wished to attend. A project Power Point presentation with handouts and samples of the screening 
tools gave nurses visuals and hands-on training.  Incentives included adding data support and 
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collection for doctoral quality improvement project to job resumes for those who participated in 
the project.  The meeting took place one week before the date of the project beginning so that 
nursing staff members were able to ask questions and voice any concerns regarding the process.  
At this meeting, the process of where to store the completed screening tools in the nursing station 
was shown, and the importance of keeping data locked for patient privacy was stressed.  
 Intervention. Upon initiation of the project, nursing staff continued throughout their 
normal day.  Per policy, the Mini-Cog is administered as part of the annual wellness visit.  The 
nurses who were conducting the annual wellness visits determined if the MoCA and FAQ 
screening tools were appropriate.  This was based on age, mental capacity, if there was anyone 
available with the patient to assist with the screening of the FAQ, and if they pass or fail the 
Mini-Cog.  The Drake QI Project- Data intake form (Appendix E), MoCA, and FAQ screening 
tools were provided to the RNs in the packet of information in the annual wellness folders to use, 
if needed.  If it was determined to continue on with the MoCA and FAQ screening tools, then 
those were conducted and the completed screening tools were placed in the locked area where 
instructed.  The DNP student came to the clinic weekly to assist with screenings, any needed 
assistance, answering questions with staff, and compiling data that had been collected.  
 Providers were notified of results so that if any interventions were necessary according to 
the judgment of the provider, they were able to initiate such.  In the case of screening tools being 
unable to be completed, they were marked as such and were excluded from data review.  The 
patients were assigned patient numbers according to the clinic Medical Record Number (MRN) 
for identifying patient factors on the screening tools.   
 Focus groups consisted of nursing staff, nursing administration, and providers who 
wished to attend and met during the project timeframe to make any necessary changes, 
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improvements, and to corroborate with the nursing staff to evaluate the project efficiency and 
value. 
 Post-Intervention. The Drake Likert Scale was given to the nursing staff and providers 
who participated in the project, and the data collection was reviewed and analyzed.  One last 
focus group/meeting after the project was completed was held to vocalize any ideas, suggestions, 
or further support from nursing staff, administration, and/or providers.  
 Data was analyzed for the effectiveness of the MoCA and FAQ screenings.  It included 
result of Mini-Cog, patient education level, person conducting the evaluation, whether or not 
other persons were present during the screenings, provider involved in care, if any intervention 
was needed and time taken to complete the screenings.  The data collection sheet was called the 
Drake QI Project- Data Intake (Appendix E).  Data included evaluating the difference between 
failed Mini-Cog screenings and failed MoCA and FAQ screenings to get a percentage.  Data also 
examined failed Mini-Cog screenings and normal MoCA and FAQ screenings as a percentage to 
look at the false positives with the Mini-Cog.  In doing this, the specificity and sensitivity was 
calculated to examine if the Mini-Cog was effective or if the MoCA and FAQ was a more 
effective use of time and resources in the annual wellness visits.  
Data Analysis 
 Mini-Cog  
The Mini-Cog is a short assessment that takes about three to five minutes to complete.  The 
screening involves memory recall of three words about three to five minutes after they are 
initially given to the participant and a clock-drawing test.  The clock-drawing test involves the 
surveyor giving the participant a time and asking the participant to draw a clock at that time with 
correctly filling in all the numbers to the clock.  One point is given for each correctly 
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remembered word for a total of three points in the recall section.  The clock is evaluated with a 
zero or two, with zero being a refusal or inability to draw the clock and a two being a normal 
clock with the correct time indicated.  This gives a possible score of five.  Cut-off points are 
indicated that a score less than three is validated for dementia screenings.  (Borson, 2015).  
Therefore, if the patient scored less than a three, they were considered to have failed the Mini-
Cog.  A score of three or above is a passed Mini-Cog.  The data was entered in as pass or fail. 
 Montreal Cognitive Assessment. 
The MoCA (Appendix A) is a brief cognitive assessment that evaluates different aspects of 
cognitive impairment that are seen in MCI and AD.  The first section is the visual/spatial section, 
where the patient is asked to complete a trail map starting at “1” and drawing a line to “A.”  
From there, the line is drawn to “2” and then to “B,” and so on.  In the next exercise, the patient 
is asked to copy the three-dimensional cube.  The clock draw is the next section.  The patient 
draws a clock and is asked to put the time at ten past eleven.  The following section is the 
naming section where the patient names the animals that are drawn.  Memory is the next part of 
the assessment, and the patient must repeat the list of words in two separate trials and then a 
recall, five minutes later.  Attention is the next section and the patient repeats the list of numbers 
that are given from the person administering the assessment and must list them in the order that 
they were given.  Then the patient is given another list of numbers and must list them back in the 
opposite order they were given.  Language is the next piece of the assessment where the patient 
repeats the sentences that are said by the interviewer.  Delayed recall follows this, and the words 
that were given earlier in the memory section should be given in any order with three tries, 
including some cues on the second and third try.  Orientation is the last section.  It asks the 
patient to provide the date, month, year, day, place, and city.  The points are indicated on the 
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exam and totaled to a possible 30 points.  A normal score is 26 or above. Data was analyzed on 
whether the patient passed with a 26 or above or failed with a score below 26.   Data was entered 
in as either pass (26 and above) or fail (below 26). 
 Functional Activities Questionnaire. The FAQ scores were measured as standardized 
with the point system that is given.  Interpretation of scores (Appendix B) includes a range from 
zero to 30.  Zero is scored as “normal” and ranges to three, being “dependent.”  A score above 
nine (where a person is dependent in three or more areas) is considered to be a score that is 
recommended to have more investigation.  (Pfeffer et al., 1982).  The data was collected 
quantitatively as those who scored zero to nine (pass) and those who scored nine and above 
(fail).  Qualitative data included if any interventions resulted from the screening and what that 
intervention was. 
 Drake Likert Scale. Data collection with the Likert scale consisted of scoring the 
surveys with each question separately and quantitatively reviewing those scores (Appendix F) 
and displaying with statistical graphs.  The comment sections were reviewed individually and 
grouped together if there were trends or similar suggestions/ideas/feedback. 
Results 
 The results of the failed Mini-Cogs and the failed Moca/FAQ’s were compared with the 
data collected and evaluated against the need for a referral.  This data was found by counting the 
number of patients and dividing that by the overall patients (who failed the Mini-Cog) and 
getting the percentage.  The number of patients who failed the Mini-Cog and passed the MoCA 
was five out of 12 patients, or 41.6%.  The number of patients who failed the Mini-Cog and 
MoCA/FAQ was seven out of 12 patients, or 58.3%.  The data also included patients who failed 
both and received referrals and/or further testing, such as lab work. This was six out of seven 
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patients, 86%.  The providers were notified when there were failed screenings and, upon further 
assessment, a referral was not warranted.  
 
Table 1 
False Positives and Referrals/Further Testing Warranted Comparisons Between Mini-Cog and 
MoCA/FAQ 
		Failed	Mini-Cog,	Passed	MoCA/FAQ 	Failed	Both	Mini-Cog	and	MoCA/FAQ 		
	Patients	Who	Failed	Both,	Who	Received	Referrals 
	41.6% 	58.3% 	86% 
 
 The time it took to complete each screening assessment was recorded by the RN and the 
average time to complete the assessments was calculated.  The average time of the Mini-Cog was 
calculated by adding up all the recorded times and dividing by the number of assessments 
completed.  The same was done for the MoCA and FAQ assessment times, and the average time 
was used as comparison.  The time and cost were evaluated by establishing an average RN salary 
in this particular clinic being $30 per hour, which equals 30 cents per minute. This was compared 
between the Mini-Cog and MoCA.  Using this information, the average time was evaluated for 
the assessments of the MoCA and FAQ as minutes taken to complete the assessment multiplied 
by the cost of the RN in minutes.  Five minutes multiplied by 30 cents per minute is $2.50; 32.92 
minutes multiplied by 30 cents per minute is $16.45. 
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Table 2 
Time and Cost Analysis and Comparison Between the Mini-Cog and MoCA/FAQ Measurement	 					Mini-Cog	 MoCA	+	FAQ	
	Average	Time	 											5	minutes	 	32.92	minutes	Average	Cost	of	RN	to	Complete	 					$2.50	 $16.45	
 
 
 However, this is a two-tiered process where the MoCA and FAQ are only administered if 
the patient fails the Mini-Cog, or at the discretion of the provider or requests from the patients.  
The total number of annual wellness visits that were completed during the timeframe was 230, 
and 12 of those failed the Mini-Cog.  This means that 5.22% of the annual wellness visits had 
patients who failed the Mini-Cog and required the further testing in this QI Project. 
 Sensitivity and specificity were also measured and compared between the Mini-Cog and 
MoCA.   National studies with the Mini-Cog and MoCA sensitivities and specificities were also 
compared. (Nasreddine, Phillips, & Chertkow, 2012; Nasreddine et al., 2005; Cullen et al., 2007; 
Carnero-Pardo et al., 2013).  Not enough data was present to include the FAQ in these 
comparisons.  
 Sensitivity is a measure of how many patients actually have an impairment and received a 
referral.  With the Mini-Cog, six out of 12 patients failed the Mini-Cog and needed a referral, 
which gives a sensitivity of 50%.   With the MoCA, six out of seven patients failed the MoCA 
and needed a referral, which gives a sensitivity of 85.7%.  Specificity is a measure of identifying 
those without the disease, correctly.  With the Mini-Cog, nine out of 14 Mini-Cog assessments 
were correct with a referral need, which is 64.3%.  The MoCA had 13/14 correct assessments 
with a referral need, giving a specificity of 92.9%. 
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Table 3 
Sensitivity and Specificity of the Mini-Cog and MoCA in the Quality Improvement Project Measurement QI	project:	Mini-Cog QI	project:	MoCA Sensitivity 50% 85.7% Specificity 64.3% 92.9% 
 
 
Table 4 
Generalized Sensitivity and Specificity of the Mini-Cog and MoCA 
Measurement Generalized	Studies:	Mini-Cog Generalized	Studies:	MoCA Sensitivity 60% 100% Specificity 90% 87-90% 
 
 The Drake Likert Scale results were compiled among the nurses that conducted the 
annual wellness visits and the memory screening assessments as described in the QI project.  
They rated each question according to their opinion, and results remained anonymous.  Each 
answer was tallied and placed in the column.  There were three nurses who completed the Drake 
Likert Survey and the lowest-scored answer was “Fair.” 
Table 5 
Tallied Scores of the Drake Likert Scale 
	Question 	Very	Poor 	Poor 	Fair 	Good 	Very	Good 1    1 2 2    2 1 3    2 1 4   1 2  5    1 2 
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Interpretation 
 In looking at the results of Table 1, there was 41.6% of the patients who took the Mini-
Cog and failed but then went on to take the MoCA and FAQ and passed.  With the current 
process, the patients who fail the Mini-Cog are automatically sent for referrals, unless the 
provider does an assessment that defers this.  Most times, the providers are using the Mini-Cog 
as the screening tool to determine if the patient should be referred for specialized treatment, lab 
work, and/or imaging.  This data capture the Mini-Cog presenting some false positives and 
triggering a referral process for patients that are scoring normally in the MoCA/FAQ 
assessments.  Often times with referrals, this can be a costly process for patients and time 
consuming as well.  The Memory Clinic and Neurology are already being bogged down by many 
referrals, and with this data, this is suggesting that some of these patients are not needing these 
referrals.  Other patients can use those office visits and the clinics can run more slowly with a 
two-tier process such as this project presented.  When furthering the process and conducting the 
MoCA and FAQ assessments, the sensitivities and specificities were much greater (Tables 3 and 
4) in getting proper and timely referrals to those patients.  The data provided in Table 1 – 86% of 
the patients failed both the Mini-Cog and the MoCA/FAQ – is meant to show that both tests 
together were not completely sensitive and specific. Some providers conducted further 
assessment and history-taking and determined that some patients did not require a referral and 
believed the cognitive impairment to be related to other conditions. 
 The sensitivities and specificities were analyzed and compared to national study results of 
the assessments, Mini-Cog and MoCA.  (Tables 3 and 4).  While the project found the Mini-Cog 
to have a much less specificity than the national published studies, it is evident that the MoCA is 
superior in both the sensitivity and specificities with the project and with nationally recognized 
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and published studies.  Limitations to the project data include a smaller sample size of 14 
patients and limited timeframe between December 2017 and March 2018.  With a larger sample 
size, one would expect the data to more closely resemble the generalized studies’ findings.  With 
the data continuing to support the MoCA and FAQ showing an improved sensitivity and 
specificity, this also correlates with the idea of getting referrals in a more timely and efficient 
manner and eliminating referrals that are not necessary.  This helps to more correctly identify 
those who actually have cognitive concern for Alzheimer’s or MCI and get them the referral and 
in a more time-efficient manner since others who don’t need the referrals are not given those 
office spots.  As this disease can be time-sensitive and starting medications for patients in the 
early stages of Alzheimer’s has shown some improvements in quality of life and allowing 
patients to be independent for longer periods of time than without the medications, time-
efficiency can be especially important in these cases.  (Kumar, Singh, & Ekavali, 2015).  Early 
diagnosis and recognition also allows these patients and their family members to plan for the 
future.  One of the goals of this project was to identify a way to allow more timely identification 
for the patients if there is cognitive decline and concern.  With evaluating the MoCA, this 
outcome was met and shown to have a better sensitivity and specificity than using the Mini-Cog 
alone. 
 Evaluating the time and cost of the further assessments is also important from business, 
nursing, and patient perspectives.  Time and resources are especially crucial in health care, and it 
is essential to evaluate this data with the project as well.  In Table 2, one can see that the Mini-
Cog takes much less time on average than the average time it took to complete the MoCA and 
FAQ assessments together.  In evaluating the cost of having an RN conduct these assessments, it 
is also evident that the cost is much greater to have the RN use more time in the assessment, 
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ultimately costing the business more money.  However, there were a total of 230 annual wellness 
visits that were conducted throughout this timeframe.  That means there was a small percentage 
of 5.22% that failed the Mini-Cog that qualified to continue on with the further assessment 
including the MoCA and FAQ.  Otherwise, if the patient passed, the further assessment was not 
needed.  Evaluating this information with the increased sensitivities and specificities of the 
MoCA and FAQ, it seems reasonable to proceed with implementing this two-tiered process that 
the project investigated.   
 Another important evaluation that was used in the data analysis was the Drake Likert 
Scale (Appendix F) to assess how the nurses who conducted the memory screening assessments 
felt about the effectiveness and usefulness of the project. (Table 5).  All the questions that the 
nurses responded to were of positive results with a response of “Fair” or greater.  In looking at 
the responses, all the nurses chose a lower response for the question on the time-efficiency of the 
MoCA and FAQ combined.  These nurses conduct several annual wellness visits on a daily basis 
and oftentimes patients are scheduled to see a provider for their annual physical after this nurse 
appointment.  Other times, these nurses have back-to-back visits scheduled for every hour, with 
these appointments taking an hour or more.  Time-efficiency and time management is crucial to 
keeping the nurses, providers, and patients on time for other appointments and is good business 
sense as well.  That is another reason why it would be important to note that the further 
MoCA/FAQ assessments are not warranted unless the patient fails the Mini-Cog.   
Discussion 
 The first goal of the QI project was to educate the nurses on the administration of the 
MoCA and FAQ screenings.  This goal was successful throughout each objective.  The first 
meeting was held on time and was successful with a PowerPoint presentation and handouts.  
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There were samples of the actual assessments and information that was requested to be collected, 
and the nurses were informed that these would be placed within the annual wellness visit folders 
for use if and when needed.  The screening tools provided a visual for the nurses to use and 
opportunities for questions as well as hands-on training to see how the MoCA is administered.  
The locked area in which the completed data was kept – in the complex care RN office – and the 
key to access the area were shown to participating nurses. The area was designated within the 
timeframe. 
 The next goal of the QI project was to hold a nursing meeting with the nurses and 
conduct focus groups throughout to address any questions, concerns, or ongoing problems.  The 
first meeting was held before the initiation of the project, and the meetings were held monthly 
thereafter.  90% of staff members who had direct care with the QI project attended the focus 
meetings, which exceeded the QI objective.  Another objective stated that providers were to be 
notified if there were positive screenings (failed Mini-Cog and MoCA) so that there was an 
opportunity to do further assessment.  100% of providers received notification of positive 
screenings. 
 Goal three of the QI project identifies goals of health care providers and their opinions on 
whether the use of the screening tools used benefitted their practice.  This goal was successful in 
each objective as 100% of the population of interest was administered the screening tools and 
86% of providers agreed that the screening tools were useful.  
 The fourth goal of the QI project was related to effectiveness.  This goal evaluated 
whether the combination of the MoCA and FAQ were more effective screening tools (when 
combined) than the Mini-Cog.  The result was both increased specificities and sensitivities with 
the MoCA and FAQ screenings, making this outcome successful. 
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 The last goal of the QI project related to population.  The goal was for the persons 65 and 
older to have positive experiences with the screening tools and process.  This goal was successful 
with the objectives, meeting 100% of individuals of interest consenting to screening and 100% of 
participants offered counseling and education regarding their results. 
 After evaluating and finding all project goals to be successful, it is suggested to 
implement a two-tiered memory screening process into the Internal Medicine Clinic.  It would 
likely benefit any clinic that sees a population of persons aged 65 and older, but with the data 
that was found within this Quality Improvement project, it clearly benefits the clinic and the 
patients.  Patients were able to have a screening process that was more accurate and allowed for 
further testing/evaluation and/or referrals to be placed more efficiently and effectively. 
Cost-Benefit Analysis/Budget 
 Budgets are necessary for projects to take place and help to further the dissemination of 
ideas and progress (Berwick & Hackbarth, 2012).  By projecting the amount of money in United 
States dollars and time costs in advance of the project initiation, the DNP student was able to 
assess the probability of implementing the project.  The development of a budget aided the DNP 
student to remain financially responsible as well as highlighting the benefits that were achieved 
through the project.  The DNP student contributed all the funds necessary to implement the 
project throughout all stages.  The financial budget for the project can be viewed in Appendix G.  
The expenses that are totaled throughout the financial budget are expenses that the DNP student 
is responsible for.  
 
Timeline 
See Appendix H. 
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Ethical Considerations/Protection of Human Subjects 
 With any project that uses the participation of humans as subjects, ethical considerations 
and rights must be addressed.  All participants were protected by the Health Insurance Portability 
and Accountability Act of 1996 (HIPAA), which protects the privacy of patients’ health 
information (Modifications to the HIPAA Privacy, Security, Enforcement, and Breach 
Notification Rules, 2013).  The DNP student and personnel who carried out this project followed 
HIPAA regulations and Standards of Care both in the hospital site and at the clinic site. Patient 
identifiers were purposely excluded to protect patient privacy in the collection of data.  The risks 
to patients participating in the project were not different from the risks of patients receiving care 
in the facility who were not participants.  Participant confidentiality was assured by coding the 
participants using individualized identification numbers.  The list of participants and their 
identifying numbers was kept locked at the nursing station and only accessible to the DNP 
student and registered nurses assisting with the project.  All electronic files containing any 
identifiable information were password-protected within the EHR to ensure privacy.  EHR are 
monitored and maintained within the facility and were kept protected under these statutes.     
Conclusion 
 Alzheimer’s Disease is a growing problem in the population that requires increased 
attention to prevention and early detection.  Most everyone knows someone who has been 
affected or is currently being affected by Alzheimer’s, whether it’s a personal family member, 
friend, or acquaintance.  Not only is it affecting our aging population, but it is also costing our 
country millions of dollars and will continue increasing.  What can we do?  We don’t know 
enough about Alzheimer’s Disease!  These are excuses, and here is a proposition to consider in 
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helping to close that gap, even if it is just a start: In order to discover, we must look.  Earlier 
identification of the disease can vastly improve the quality of life and the overall outcomes, and 
in some cases can even slow or stop the progression.  The use of validated screening tools such 
as the MoCA and FAQ together can help to identify individuals who are at risk at an earlier stage 
before symptoms have even begun.  Offering this to individuals and families may help to 
improve the disease prognosis and offer better quality of life.  Implications for the future include 
earlier identification and treatment modalities of impairment.  With more interest and education 
being invested in this population, treatments will continue to be researched, facilities will be 
dedicated to assist with the special needs of these patients, and public knowledge will improve.    
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Appendix A 
Montreal Cognitive Assessment (MoCA)
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Appendix B 
Functional Activities Questionnaire (FAQ) 
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Initial Dementia Assessment
Attachment 3—Functional Activities Questionnaire (FAQ)
The FAQ is an informant-based measure of functional abilities. Informants provide perfor-
mance ratings of the target person on ten complex higher-order activities.
Individual Items of the FAQ
1.   ____Writing checks, paying bills, balancing checkbook
2.   ____Assembling tax records, business affairs, or papers
3.   ____Shopping alone for clothes, household necessities, or groceries
4.   ____Playing a game of skill, working on a hobby
5.   ____Heating water, making a cup of coffee, turning off stove
6.   ____Preparing a balanced meal
7.   ____Keeping track of current events
8.   ____Paying attention to, understanding, discussing a TV show, book, magazine
9.   ____Remembering appointments, family occasions, holidays, medications
10. ____Traveling out of neighborhood, driving, arranging to take buses
Total ________
The levels of performance assigned range from dependence to independence and are rated
as follows.
•   Dependent = 3
•   Requires assistance = 2
•   Has difficulty, but does by self = 1
•   Normal = 0
Two other response options can also be scored.
•   Never did (the activity), but could do now = 0
•   Never did, and would have difficulty now = 1
A total score for the FAQ is computed by simply summing the scores across the 10 items.
Scores range from 0 to 30. A cutpoint of 9 (dependent in 3 or more activities) is recom-
mended.
Source:
Pfeffer, R., T. Kurosaki, C. Harrah, J. Chance, and S. Filos. 1982. “Measurement of Functional Activities of
Older Adults in the Community.” Journal of Gerontology 37 (May):323–9. Reprinted with permission of The
Gerontological Society of America, 1030 15th Street NW, Suite 250, Washington, DC 20005. Reproduced by
permission of the publisher via Copyright Clearance Center, Inc.
Revised April 1999
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Appendix C 
Mini-Cog Test 
 
 
Borson, S. Mini-Cog.  Retrieved from http://mini-cog.com/wp-
content/uploads/2015/12/Universal-Mini-Cog-Form-011916.pdf  
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Appendix D 
Kurt Lewin’s Three-Step Model for Change 
 
 
 
 
 
 
 
 
Source: Google image 1 Kurt Lewin’s et al. (1939) 
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Appendix E 
Drake Quality Improvement Project- Data Intake  
Date       ________________________________________ 
 
MRN #   ________________________________________ 
 
DOB    ________________________________________ 
 
Level of Education of Subject  
 
   ________________________________________ 
 
 
Person Performing Screening 
    
      ________________________________________ 
 
Other Persons Present (relation to subject, not names) 
 
      
_________________________________________________________________________ 
 
Provider  ______________________________________ 
 
Verbal Consent (Y/N) 
 
Mini-Cog Score_______________ 
 
Time to Complete MoCA and FAQ (in minutes) _______________________ 
 
Interventions needed? 
 
 ____________________________________________________________________ 
 
 ____________________________________________________________________ 
 
 
 
 
Drake, K. D. (2017). Drake QI Project-Data Intake© 
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Appendix F 
Drake Likert Scale: Evaluating Alzheimer’s Dementia Screening Quality Improvement 
Project   
Please complete the following survey with specific regard to the above enquiry, by placing a 
circle on the appropriate response that best applies to you. Select only one response per 
question. The responses are on a 5-point Likert scale with 1= strongly disagree; 2= disagree; 3= 
neither or N/A; 4= agree; and 5= strongly agree. Please do not write your name or date of birth 
on this survey. All responses are kept confidential. 
 
1.  How effective do you think the MoCA screening tool is? 
Very Poor  Poor  Fair  Good  Very Good 
2.  How effective do you think the FAQ screening tool is? 
Very Poor  Poor  Fair  Good  Very Good 
3.  How effective do you think the combination of MoCA and FAQ screening tools are? 
Very Poor  Poor  Fair  Good  Very Good 
4.  How do you feel the combinations of the two are in terms of time-efficiency? 
Very Poor  Poor  Fair  Good  Very Good 
5.  How would you rate your recommendation to repeat this project at another site? 
Very Poor  Poor  Fair  Good  Very Good 
6. Comments/ Questions/ Suggestions   
Legend:  
Very Poor= 0     Poor= 1     Fair=2    Good=3     Very Good=4 
Drake, K. D. (2017). Drake Likert Scale©   
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Appendix G 
Financial Budget 
 
Item	 Cost	
Physical	Materials	2	reams	of	standard	white	8x11.5”	printing	paper	 $14.00	1	18-pack	of	standard	black	ballpoint	pens	 $5.00	Copying/	Printing	of	project	handouts/	Drake	Likert	surveys/Drake	QI	Project-	Data	Intake	 $17.00	Food	supply	for	first	nursing	meeting	 $20.00	
Computer	Information	Systems	Laptop	equipped	with	Microsoft	Excel	and	SPSS	software	 $1,500.00	(not	included	in	total	cost	of	project	as	this	is	owned	by	the	DNP	student)	
Personnel	DNP	as	project	investigator	 3	credits	($750	per	credit)=	$2,250.00	(Not	included	in	total	cost	given	educational	benefits	of	project	incurred	by	DNP	student)	
Registered	Nurse		 RN	is	$30/hr.		Total	screening	took	and	average	of	32.92	minutes	which	is	$16.45.	There	were	a	total	of	14	participants.	14x	16.45	=	230.30	
Transportation/	Travel	Travel	expenses	to/from	clinic	setting	(private	car)	 $10	per	round	trip	x	8	trips	=	$80.00	
Project	Space	for	Program	Implementation	Meeting	spaces	(located	within	practice	settings	in	both	locations)	 No	cost	(available	free	of	charge	within	practice	setting.		I.e.	nursing	break	room,	conference	room)	
Total	Cost/Expenses		
Total	Estimated	Cost		 $366.30	
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Appendix H 
Timeline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Task	 October	 November	 December	 January	 February	 March	 April	Proposal	Approval X	 	 	 	 	 	 	Nursing	Meeting X	 X	 	 X	 X	 X	 	Recruitment	of	Eligible	Participants 	 	 X	 X	 X	 X	 	Data	Collection 	 	 X	 X	 X	 X	 	Educational	Intervention 	 	 	 X	 X	 X	 	Data	Analysis 	 	 	 	 	 X	 X	Post-Test	and Analysis	of	Outcomes 	 	 	 	 	 X	 X	Results	Presented	to	Local	Providers 	 	 	 	 	 	 X	
ALZHEIMER’S DEMENTIA SCREENING 64 
 
Appendix I 
MoCA Screening Tool Approval 
Hello, 
	 
Universities/Foundations/Health	Professionals/Hospitals/Clinics/Public	Health	Institutes	may	
use,	reproduce,	and	distribute	the	MoCA©	for	clinical	practice	without	permission.	The	test	
should	be	made	available	free	of	charge	to	patients.	Written	permission	and	Licensing	
Agreement	is	required	if	funded	by	commercial	entity	or	pharma. 
Thank-you	for	your	interest	in	the	MoCA©, 
	 
 
	 
Kathleen	Gallant,	MSOT	Occupational	Therapist/		
Psychometrician	On	behalf	of	Dr	Ziad	Nasreddine,		
Neurologist,	MoCA©	Copyright	Owner 
MoCA	Clinic	&	Institute 
4896	Taschereau	Blvd,	suite	230 
Greenfield	Park,	Quebec,	Canada,	J4V	2J2 
Tel	:	(450)	672-7766	#222	Fax	:	(450)	672-3899 
kathleen.gallant@mocaclinic.ca 
www.mocatest.org	/	www.alzheimer.TV	
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Appendix J 
FAQ Screening Tool Approval 
GratPerm 
Please	be	advised	that	this	permission	has	been	granted	on	the	basis	that	no	pharma	or	
healthcare	companies	are	directly	involved	or	sponsoring	this	reuse.	If	any	pharma	or	healthcare	
companies	are	involved	additional	permission	will	be	required 
	 
Dear	Kirstin, 
RE:	FAQ	tool.	R.	I.	Pfeffer	et	al.	Measurement	of	Functional	Activities	in	Older	Adults	in	the	
Community.	Journal	of	Gerontology	(1982)	37	(3):	323-329 
	 
Thank	you	for	your	email	requesting	permission	to	reprint	the	above	material.	Our	permission	
is	granted	without	fee	to	reproduce	the	material. 
Use	of	the	OUP	Material	is	restricted	to:	Inclusion	in	the	forthcoming	research	study,	
‘Alzheimer’s	Dementia	Screening	in	Primary	Care:	Quality	Improvement	Project	to	Identify	
Those	at	Risk’,	to	be	screened	in	print	and	electronic	format	by	up	to	4	administrators	(NB:	the	
©	line	must	appear	on	the	same	page	as	the	OUP	material	and	the	placing	of	material	on	open-
access	websites	is	prohibited).	Institution:	University	of	Massachusetts.	Permission	Time	Period:	
1	Year.	Total	Number	of	End	Users:	70.	Territory:	USA.	Language:	English.	Non-Commercial	Use	
Only. 
	
This	permission	is	limited	to	this	particular	use	and	does	not	allow	you	to	use	it	elsewhere	or	
in	any	other	format	other	than	specified	above. 
Please	include	a	credit	line	in	your	publication	citing	full	details	of	the	Oxford	University	Press	
publication	which	is	the	source	of	the	material	and	by	permission	of	Oxford	University	Press/	on	
behalf	of	the	sponsoring	society	if	this	is	a	society	journal. 
	 
If	the	credit	line	or	acknowledgement	in	our	publication	indicates	that	material	including	any	
illustrations/figures	etc	was	drawn	or	modified	from	an	earlier	source	it	will	be	necessary	for	
you	to	also	clear	permission	with	the	original	publisher.		If	this	permission	has	not	been	
obtained,	please	note	that	this	material	cannot	be	included	in	your	publication/photocopies. 
	 
Miss	Louise	Eyre	|	Permissions	Assistant	|Rights	Department	 
Academic	and	Journals	Divisions|Global	Business	Development	 
Oxford	University	Press	|	Great	Clarendon	Street	|	Oxford	|	OX2	6DP	 
Tel:	+44(0)1865	354454|	Email:	louise.eyre@oup.com	|	www.oxfordjournals.org	 
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Appendix K 
 
Human Subjects Determination Form 
 
 
 
